Selection criterion < Selegiline < Selegiline (L‐deprenyl)

Facettes :

List of bibliographic references indexed by Selegiline

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
003584 (2006)	Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]	Association between amantadine and the onset of dementia in Parkinson's disease
003A84 (2004)	Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
003E24 (2004)	Susan Hollán [Hongrie] ; Lászl Vécsei [Hongrie] ; Kálmán Magyar [Hongrie]	Adverse effects of dopamine potentiation by long‐term treatment with selegiline
004250 (2002)	Manavdeep Grewal [Canada] ; Raed Hawa [Canada] ; Colin Shapiro [Canada]	Treatment of periodic limb movements in sleep with selegiline HCl
004346 (2002)	Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis]	Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
004594 (2002)		Treatment of depression in idiopathic Parkinson's disease
004606 (2002)		MAO-B inhibitors for the treatment of Parkinson's disease
004C42 (1999)	A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
004D56 (1999)	Robert B. Innis ; Kenneth L. Marek ; Kim Sheff ; Sami Zoghbi ; Joseph Castronuovo [États-Unis] ; Andrew Feigin [États-Unis] ; John P. Seibyl	Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
004F03 (1998)	Andreas Kupsch [Allemagne] ; Oertel [Allemagne]	Selegiline, pregnancy, and Parkinson's disease
004F04 (1998)	Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
004F18 (1998)	Peter Hagell [Suède] ; Per Odin [Allemagne] ; Ellen Vinge [Suède]	Pregnancy in Parkinson's disease: A review of the literature and a case report
005093 (1998)	Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; Heidi Shale [États-Unis] ; Simon Pedder [États-Unis] ; Ernest E. Dorflinger [États-Unis]	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
005171 (1998)	C. W. Olanow [États-Unis] ; C. Mytilineou [États-Unis] ; W. Tatton [États-Unis]	Current status of selegiline as a neuroprotective agent in Parkinson's disease
005235 (1997)	LeWitt [États-Unis] ; David Oakes [États-Unis] ; Lu Cui [États-Unis]	The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
005237 (1997)	Larsen [Norvège] ; Jette Boas [Danemark]	The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study
005259 (1997)	Lyytinen [Finlande] ; Seppo Kaakkola [Finlande] ; Sirpa Ahtila [Finlande] ; P Ivi Tuomainen [Finlande] ; Heikki Ter V Inen [Finlande]	Simultaneous MAO‐B and COMT inhibition in L‐dopa‐treated patients with parkinson's disease
005265 (1997)	Hauser [États-Unis] ; Theresa A. Zesiewicz [États-Unis]	Sertraline for the treatment of depression in parkinson's disease
005428 (1997)	Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]	A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
005448 (1997)	P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis]	The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol
005450 (1997)	J. P. Larsen [Norvège] ; J. Boas [Danemark]	The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Selegiline" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Selegiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Selegiline
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024